Mayo Clinic Researcher Describes Research in Tissue Engineering (A small molecule MST1/2 inhibitor accelerates murine liver regeneration with improved survival in models of steatohepatitis).

Předmět:	LIVER regeneration TISSUE engineering SMALL molecules RESEARCH personnel FATTY liver
Zdroj:	Blood Weekly; 3/21/2024, p305-305, 1p
Abstrakt:	A recent study conducted at the Mayo Clinic in Rochester, Minnesota, explored the use of a small molecule inhibitor called mCLC846 to accelerate liver regeneration in diseased models. The researchers found that oral delivery of mCLC846 resulted in improved survival and accelerated liver regeneration in models of diet-induced steatohepatitis. The compound demonstrated on-target inhibition of serine/threonine kinase 4/3 (MST1/2) and reduced epidermal growth factor receptor (EGFR) inhibition. The study suggests that pharmacological acceleration of liver regeneration with mCLC846 could be a feasible therapeutic option for patients requiring surgical resection. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu